Browse EX-10 agreements

EIGHTH AMENDMENT TO CREDIT AGREEMENT

EIGHTH AMENDMENT TO CREDIT AGREEMENT, dated as of October 9, 2026 (this “Amendment”), is by and among GRAY MEDIA, INC., a Georgia corporation (the “Borrower”), the other Guarantors party hereto (together with the Borrower, the “Loan Parties”) and WELLS FARGO BANK, NATIONAL ASSOCIATION (“Wells Fargo”), as administrative agent (in such capacity, the “Administrative Agent”) and the Eighth Amendment Incremental Term G Lender (as defined below). Unless otherwise indicated, all capitalized terms used herein and not otherwise defined herein shall have the respective meanings provided such terms in the Amended Credit Agreement referred to below.

W I T N E S S E T H:

…

SEPARATION AGREEMENT AND RELEASE OF CLAIMS

This Separation Agreement and Release of Claims (“Agreement”) is entered into by and between Myriad Genetics, Inc. (together with its subsidiaries, affiliates, successors and assigns, the “Company”) and Brian Donnelly (“Executive” and together with the Company, the “Parties” and each a “Party”).

WHEREAS, Executive was employed by the Company as the Company’s Chief Commercial Officer;

WHEREAS, the Parties executed a Severance and Change in Control Agreement on May 1, 2025 (the “Severance Agreement”); and

WHEREAS, Executive’s employment with the Company has terminated, and the parties desire to resolve any and all disputes or potential disputes that may exist between them, including, but not limited to, those relating to Executive’s employment with, or separation from, the Company.

NOW THEREFORE, in consideration of the mutual promises made herein, the Parties agree as follows:

…

FOURTH SUPPLEMENTAL INDENTURE

THIS FOURTH SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of October 9, 2026, by and among INNOVATE Corp. (f/k/a HC2 Holdings, Inc.), a Delaware corporation (the “Company”), the subsidiary guarantors party to the Indenture referred to below (the “SubsidiaryGuarantors”) and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”) and collateral trustee (the “Collateral Trustee”) under the Indenture referred to below.

W I T N E S S E T H

WHEREAS, the Company and Subsidiary Guarantors have heretofore executed and delivered to the Trustee and the Collateral Trustee an indenture, dated as of August 4, 2025 (as supplemented and amended through the date hereof, the “Indenture”), providing for the issuance of 9.5% Convertible Senior Secured Notes due 2027 (the “Notes”);

WHEREAS, Section 16.02 of the Indenture provides that the Company may amend or supplement certain provision of the Indenture with the consent of the Holder of each outstanding Note affected thereby;

…

SL SCIENCE HOLDING LIMITED

2026 SHARE INCENTIVE PLAN

ARTICLE 1

PURPOSE

The purpose of this 2026 SHARE INCENTIVE PLAN is to promote the success and enhance the value of SL Science Holding Limited, a Cayman Islands exempted company (the “Company”), by linking the personal interests of the Directors, Employees, Consultants, and other Persons to those of the Company’s shareholders and by providing such individuals with an incentive for outstanding performance to generate superior returns to the Company’s shareholders. The Plan is further intended to provide flexibility to the Company in its ability to motivate, attract, and retain the services of the above individuals upon whose judgment, interest, and special effort the successful conduct of the Company’s operation is largely dependent.

ARTICLE 2

DEFINITIONS AND CONSTRUCTION

Wherever the following terms are used in the Plan they shall have the meanings specified below, unless the context clearly indicates otherwise. The singular pronoun shall include the plural where the context so indicates.

…

* Portions of this exhibit have been omitted in accordance with Item 601(b)(10) of Regulation S-K.

TERMINATION LETTER

This Termination Letter (this “Letter”) is entered into as of October 8, 2026 in Suzhou, Jiangsu Province, the People’s Republic of China, by and among the following parties:

Party A: Jiangsu Li Bang Intelligent Technology Co., Ltd.

Unified Social Credit Code: [           ]

Address: No. 190, Xizhang Road, Gushan Town, Jiangyin City

Legal Representative: Huang Feng

Party B:

Party B-1: [           ], PRC ID No. [           ]

Party B-2: [           ], PRC ID No. [           ]

Party B-3: [           ], PRC ID No. [           ]

RECITALS:

WHEREAS, the Parties entered into that certain Equity Transfer Agreement dated April 17, 2026 (the “Agreement”); and

WHEREAS, the Parties do not deem the Agreement final and binding in accordance with Article 10 thereof, have not reached a definitive understanding with respect to the equity transfer transaction contemplated by the Agreement, and wish to terminate the Agreement accordingly.

…

**CONVERTIBLE NOTE CANCELLATION AND **

CAPITAL CONTRIBUTION AGREEMENT

This Convertible Note Cancellation and Capital Contribution Agreement (the “Agreement”) is entered into as of March 31, 2026 (the “Effective Date”), by and between:

Wewards, Inc., a Nevada corporation (the “Company”), and Lei Pei, sole owner and beneficiary of Sky Rover Holdings, LTD, an individual/entity and shareholder of the Company (the “Holder”).

The Company and the Holder may be referred to individually as a “Party” and collectively as the “Parties.”

WHEREAS, the Company previously issued Convertible Promissory Notes dated February 28, 2017 and November 20, 2017 (collectively, the “Notes”) to Sky Rover Holdings, LTD., an entity solely owned by the Holder in the original principal amounts of $2,500,000 and $8,000,000, respectively;

WHEREAS, pursuant to the Notes, interest has accrued on the outstanding principal balance;

WHEREAS, as of the Effective Date, the obligations under the Notes consist of:

…

Aspen Neuroscience, Inc.

INDEMNIFICATION AGREEMENT

This Indemnification Agreement, dated [_______], 2026, is made between Aspen Neuroscience, Inc., a Delaware corporation (the “Company”), and [______________] (the “Indemnitee”).

RECITALS

WHEREAS, the Company desires to attract and retain the services of talented and experienced individuals, such as Indemnitee, to serve as directors and officers of the Company and its subsidiaries and wishes to indemnify its directors and officers to the maximum extent permitted by law;

WHEREAS, the Company and Indemnitee recognize that corporate litigation in general has subjected directors and officers to expensive litigation risks;

…

ASPEN NEUROSCIENCE, INC.

2026 EQUITY INCENTIVE PLAN

NOTICE OF GRANT OF RESTRICTED STOCK UNITS

Aspen Neuroscience, Inc., a Delaware corporation (the “Company”), has granted to the Participant an award (the “Award”) of certain units pursuant to the Aspen Neuroscience, Inc. 2026 Equity Incentive Plan (the “Plan”), each of which represents the right to receive on the applicable Settlement Date one (1) share of Stock. The Award is subject to all of the terms and conditions as set forth in this Notice of Grant of Restricted Stock Units (“Grant Notice”), and in the Plan and the Restricted Stock Units Agreement (“RSU Agreement”), both of which are attached hereto and incorporated herein in their entirety. Capitalized terms not otherwise defined herein will have the meanings set forth in the Plan or the RSU Agreement both of which are available through the Company’s then-current electronic stock administration system (the “Equity Administration System”).

The blank fields below shall be deemed to come from the Company’s Equity Administration System, as follows:

…

Aspen Neuroscience, Inc.

Loan Forgiveness and Option Amendment Agreement

This Loan Forgiveness and Option Amendment Agreement (this “Agreement”) is entered into as of September 25, 2026 (the “Effective Date”), by and between Aspen Neuroscience, Inc., a Delaware corporation (the “Company” or “Aspen”), and Andrew Spaventa (“Mr. Spaventa”). Each of Aspen and Mr. Spaventa is referred to herein individually as a “Party” and collectively as the “Parties” to this Agreement.

RECITALS

WHEREAS, Mr. Spaventa previously executed certain stock options to purchase shares of Common Stock of the Company pursuant to a Stock Option Agreement dated September 25, 2020;

WHEREAS, in connection with such option exercises, Mr. Spaventa executed the following Secured Full Recourse Promissory Note in favor of the Company: Secured Full Recourse Promissory Note dated February 8, 2021, in the original principal amount of $61,240.55 (the “Note”);

…

***Certain information has been excluded from this exhibit because it is both (i) not material and (ii) the type that the registrant customarily and actually treats as private or confidential. Such omitted information is indicated by brackets (“[***]”) in this exhibit***

August 18, 2026

Aspen Neuroscience, Inc.

10835 Road to the Cure, Ste. 100

San Diego, CA, 92121

Attention: Damien McDevitt, President & CEO

E-mail: [***]

Ladies and Gentlemen:

Aspen Neuroscience, Inc., a Delaware corporation (“Aspen”), and Cell X Technologies, Inc., a Delawarecorporation (the “Cell X”), hereby agree upon the satisfaction (as determined in the reasonable discretion of Cell X and Aspen) of all of the Conditions (as defined below), Aspen and Cell X shall execute an Amendment to Secured Convertible Promissory Note Purchase Agreement, Secured Convertible Promissory Note and Side Letter and Security Interest Termination Agreement, in the form attached hereto as Exhibit A(the “Amendment”), and consummate the transactions contemplated thereby.

…

***Certain information has been excluded from this exhibit because it is both (i) not material and (ii) the type that the registrant customarily and actually treats as private or confidential. Such omitted information is indicated by brackets (“[***]”) in this exhibit***

TORREY PINES SCIENCE PARK

LEASE

This Lease (the “Lease”) dated as of the date set forth in Section 1of the Summary of Basic Lease Information (the “Summary”) below, is made by and between HCP TPSP, LLC, a Delaware limited liability company (“Landlord”) and ASPEN NEUROSCIENCE, INC., a Delaware corporation (“Tenant”).

SUMMARY OF BASIC LEASE INFORMATION

…

	Incentive Stock Option		Participant:
	Nonstatutory Stock Option		Date:

STOCK OPTION EXERCISE NOTICE

Aspen Neuroscience, Inc.
Attention: Chief Financial Officer

Ladies and Gentlemen:

1.

Option.I was granted an option (the “Option”) to purchase shares of the common stock (the “Shares”) of Aspen Neuroscience, Inc. (the “Company”) pursuant to the Company’s 2018 Stock Plan (the “Plan”), my Notice of Grant of Stock Option (the “Grant Notice”) and my Stock Option Agreement (the “Option Agreement”) as follows:

…